Skip to main
ONC

BeiGene Ltd (ONC) Stock Forecast & Price Target

BeiGene Ltd (ONC) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 38%
Buy 62%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BeOne Medicines is a promising biotech company with a strong financial outlook, thanks to its highly successful commercialized drug Brukinsa which makes up for 74% of the company's total revenue. With a diverse and active pipeline, the company is well-positioned to continue its success in the highly competitive market, competing with major players such as AbbVie and AstraZeneca. However, potential risks in the industry, such as competition and regulatory challenges, should be carefully monitored for any potential impact on the company's growth.

Bears say

BeOne Medicines is showing promising solid tumor assets at the ASCO event, with a global leadership in Brukinsa and two other approved drugs generating revenue mainly in China. While facing competition from AbbVie and AstraZeneca, the company has over 50 drugs in clinical trials in its active pipeline, supporting its potential for success in the coming years. However, risks to consider include commercial, pipeline/regulatory, reimbursement, and competitive risks, which may impact its valuation.

BeiGene Ltd (ONC) has been analyzed by 13 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 62% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BeiGene Ltd (ONC) Forecast

Analysts have given BeiGene Ltd (ONC) a Buy based on their latest research and market trends.

According to 13 analysts, BeiGene Ltd (ONC) has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $404.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $404.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BeiGene Ltd (ONC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.